Rescuing patients from the rule of efficiency: A need to debate the 'rule of rescue'

PharmacoEconomics

Volumn 21, Issue 9, 2003, Pages 681-

  Kessabi, Sophia ^a   De Abreu Lourenco, Richard ^b   Wonder, Michael ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Novartis Pharmaceut Australia P   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMYOTROPHIC LATERAL SCLEROSIS; DECISION MAKING; HEALTH CARE POLICY; HUMAN; LETTER; LIFE EXPECTANCY; MEDICAL DECISION MAKING; MEDICAL ETHICS; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RESOURCE ALLOCATION; TREATMENT INDICATION;

EID: 0038352092     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200321090-00006     Document Type: Letter

References (2)

1. Freemantle N, Bloor K, Eastaugh J. A fair innings for NICE? Pharmacoeconomics 2002; 20 (6): 389-91
2. Positive recommendation made by the PBAC in September 2001 for Imatinib mesylate in CML [online]. Available from URL: http://www.health.gov.au/pbs/listing/pbacrec/ pbacrecsept01.htm [Accessed 2003 May 12]